放射性碘间接标记抗体方法的研究进展

李楠; 李培勇

放射性碘间接标记抗体方法的研究进展

李楠 , 李培勇

文章导航 > 国际放射医学核医学杂志 > 2008, 32 > 5: (260-263)

引用本文:

Citation:

放射性碘间接标记抗体方法的研究进展

李楠,
李培勇

200025 上海, 上海交通大学瑞金医院核医学科

The recent development of the strategy for indirect antibody radiolabel with iodine

LI Nan,
LI Pei-yong

Department of Nuclear Medicine, Shanghai Ruijing Hospital Affiliated Shanghai Jiaotong University, Shanghai 200025, China

摘要: 放射性碘标记单克隆抗体已广泛应用于临床疾病的诊治。内化型抗体的应用越来越受到重视,常规运用的碘直接标记法包括Iodogen标记法、氯胺-T标记法等,制备的碘标记单克隆抗体在体内容易脱碘和损伤抗体免疫活性的特性而阻碍了其在体内应用。如何对抗体进行有效的碘标记来减少体内脱碘和抗体免疫活性损伤,对运用碘标记抗体进行肿瘤治疗是十分重要的,研究表明,间接标记法是一种较为恰当的方案。
- 同位素标记 /
- 碘放射性同位素 /
- 抗体,单克隆
Abstract: Radioiodine labeled monoclonal antibodies have been widely used in the diagnosis and treatment of diseases.With the more and more attention which is attached to the application of the internalized McAb.The usual direct labeling methods, including Iodogen and chloramine-T, lead to obvious deiodination and decline of the McAb's immunological activity which impede their utilization in vivo.There is great importance for the tumor treatment with the radioiodine labeled antibodies to invent a new method in order to avoid the disadvantage described above.It is showed that indirect labeling way is a suitable strategy.In this review, we are introducing the recent advance of this method.
- Isotope label /
- Iodine radioisotopes /
- Antibodies, momeclonal
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Lambrecht FY,Durkan K,Yildirim Y,et al.Labeling of acetaminophen with 1-131 and biodistribution in rats[J].Chem Pharm Bull (Tokyo),2006,54(2):245-247.
[2]	Panjideh H,Da Silva Coelho VC,Demedde J,et al.Biodistribution and efficacy of [¹³¹I]A33scFv:CDy,a recombinant antibody-enzyme protein for colon cancer[J].Int J Oncol,2008,32(4):925-930.
[3]	Stein R,Govindan SV,Hayes M,et al.Advantage of a residualizing iodine radiolabel in the therapy of a colon cancer xenograft targeted with an anticarcino embryonic antigen monoclonal antibody[J].Clin Cancer Res,2005,11(7):2727-2734.
[4]	Reist CJ,Archer GE,Kurpad SN,et al.Tumor-specific antiepidermal growth factor receptor variant III monoclonal antibodies:use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts[J].Cancer Res,1995,55(19):4375-4382.
[5]	Gereben B,Zeold A,Dentice M,et al.Activation and inactivation of thyroid hormone by deiodinases:Local action with general consequences[J].Cell Mol Life Sci,2008,65(4):570-590.
[6]	Köhrle J.Thyroid hormone metabolism and action[J].Z Arztl Fortbild Qualitatssich,2004,98(Suppl 5):17-24.
[7]	Bianco AC,Larsen PR.Cellular and structural biology of the deiodinases[J].Thyroid,2005,15(8):776-786.
[8]	Pujals S,Fernandez-Carneado J,Ludevid MD,et al.D-SAP:a new,noncytotoxie,and fully protease resistant cell-penetrating peptide[J].ChemMedChem,2008,3(2):296-301.
[9]	Govindan SV,Stein R,Qu Z,et al.Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody:advantage of a residualizing iodine radiolabel[J].Breast Cancer Res Treat,2004,84(2):173-182.
[10]	Stein R,Govindan SV,Mattes M J,et al.Improved iodine radiolabels for monoclonal antibody therapy[J].Cancer Res,2003,63(1):111-118.
[11]	Holmberg M,Stibius KB,Ndoni S,et al.Protein aggregation and degradation during iodine labeling and its consequences for protein adsorption to biomaterials[J].Anal Biochem,2007,361(1):120-125.
[12]	Hayes DF,Noska MA,Kufe DW,et al.Effect of radioiodination on the binding of monoclonal antibody DF3 to breast carcinoma cells[J].Nucl Med Biol,1988,15(3):235-241.
[13]	Song SH,Jung KH,Paik JY,et al.Distribution and pharmaeokinetie analysis of angiostatin radioiodine labeled with high stability[J].Nuel Med Biol,2005,32(8):845-850.
[14]	Bolton AE,Hunter WM.The labelling of proteins to high specific radioactivities by conjugation to a ¹²⁵I-containing acylating agent[J].Biochem J,1973,133(3):529-539.
[15]	Vaidyanathan G,Zalutsky MR.Preparation of N-succinimidyl 3-[^*I]iodobenzoate:an agent for the indirect radioiodination of proteins[J].Nat Protoc,2006,1(2):707-713.
[16]	Zalutsky MR,Xu FJ,Yu Y,et al.Radioiodinated antibody targeting of the HER-2/neu oncoprotein:effects of labeling method on cellular processing and tissue distribution[J].Nucl Med Biol,1999,26(7):781-790.
[17]	Reist C J,Garg PK,Alston KL,et al.Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate[J].Cancer Res,1996,56(21):4970-4977.
[18]	Michihara A,Toda K,Kubo T,et al.Disruptive effect of chloroquine on lysosomes in cultured rat hepatocytes[J].Biol Pharm Bull,2005,28(6):947-951.
[19]	Shankar S,Vaidyanathan G,Kuan CT.Antie pidermal growth factor variant III scFv fragment:effect of radioiodination method on tumor targeting and normal tissue clearance[J].Nucl Med Biol,2006,33(1):101-110.
[20]	Vaidyanathan G,Affleck DJ,Bigner DD,et al.Improved xenograft targeting of tumor-speeific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomet-hyl-3-iodobenzoate[J].Nucl Med Biol,2002,29(1):1-11.
[21]	Shankar S,Vaidyanathan G,Affleck D J,et al.Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[¹³¹I]iodo-4-phosphonomethylbenzoate ([¹³¹I]SIPMB),a negatively charged substituent bearing acylation agent[J].Nucl Med Biol,2004,31(7):909-919.
[22]	Foulon CF,Welsh PC,Bigner DD,et al.Positively charged templates for labeling internalizing antibodies:comparison of Nsuccinimidyl 5-iodo-3-pyridinecarboxylate and the D-amino acid peptide KRYRR[J].Nucl Med Biol,2001,28(7):769-777.
[23]	Foulon CF,Reist CJ,Bigner DD,et al.Radioiodination via Damino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody[J].Cancer Res,2000,60(16):4453-4460.
[24]	Kobayashi H,Le N,Kim IS,et al.The pharmacokinetic characteristics of glycolated humanized anti-Tac Fabs are determined by their isoelectric points[J].Cancer Res,1999,59(2):422-430.
[25]	Jones-Wilson TM,Deal KA,Anderson CJ,et al.The in vivo behavior of Copper-64-1abeled azamacrocyclic complexes[J].Nucl Med Biol,1998,25(6):523-530.
[26]	Akizawa H,Uehara T,Arano Y.Renal uptake and metabolism of radiopharmaceuticals derived from peptides and proteins[J].Adv Drug Delive Rev,2008,60(12):1319-1328.

[1]	洪智慧 , 周小林 , 石怡珍 , 刘增礼 . ¹³¹I标记抗胃泌素释放前体单链抗体的制备及其稳定性和免疫活性研究. 国际放射医学核医学杂志, 2010, 34(2): 107-109. doi: 10.3760/cma.j.issn.1673-4114.2010.02.013
[2]	肖晴 , 潘芯 , 李崇佼 , 蒋亚群 , 王怡春 , 文兵 , 雷萍 , 何勇 . 转铁蛋白受体靶向分子探针⁹⁹Tc^m-T7的放射性标记及肿瘤显像研究. 国际放射医学核医学杂志, 2022, 46(4): 223-229. doi: 10.3760/cma.j.cn121381-202110017-00167
[3]	苏燕 , 王峰 , 王自正 , 孟庆乐 , 张乐乐 , 蒋娥 . ¹³¹Ⅰ-Tyr-octreotide的标记方法学及其生物学分布的研究. 国际放射医学核医学杂志, 2007, 31(5): 257-260.
[4]	薛艳 , 安瑞芳 , 喻明启 , 王姝 , 谢丽 . _99mTc标记抗β-人绒毛膜促性腺激素单克隆抗体. 国际放射医学核医学杂志, 2007, 31(2): 68-69.
[5]	邵虹 , 吴靖川 , 卢调章 . 单克隆抗体的^99mTc标记. 国际放射医学核医学杂志, 1996, 20(2): 60-65.
[6]	夏伟 , 吕中伟 , 王国玉 , 侯仁花 , 蔡海东 , 袁雪宇 . ⁹⁹Tc^m标记depreotide及与肺腺癌A549细胞亲和性研究. 国际放射医学核医学杂志, 2010, 34(4): 193-197. doi: 10.3760/cma.j.issn.1673-4114.2010.04.001
[7]	王立凯 , 黄丽娟 , 潘学继 , 张续 , 董全文 . 人附睾蛋白4单克隆抗体与免放试剂盒的制备及其对卵巢癌诊断的临床价值探讨. 国际放射医学核医学杂志, 2016, 40(3): 183-186, 207. doi: 10.3760/cma.j.issn.1673-4114.2016.03.005
[8]	尤徐阳 , 万卫星 . 放射免疫显像及其在胰腺癌研究中的应用. 国际放射医学核医学杂志, 2008, 32(5): 264-267,271.
[9]	范光磊 , 吴翼伟 , 章斌 . 用^99mTc标记胰岛素样生长因子1类似物的方法学研究. 国际放射医学核医学杂志, 2007, 31(4): 208-211.
[10]	安杰 , 李亚渊 , 武志芳 , 李思进 . 纳米载体的放射性核素标记方法研究进展. 国际放射医学核医学杂志, 2023, 47(3): 169-174. doi: 10.3760/cma.j.cn121381-202210013-00284
[11]	朱沭 , 赵明 , 陈璟 . 核酸及其类似物的常见放射性核素标记及显像. 国际放射医学核医学杂志, 2011, 35(1): 44-48. doi: 10.3760/cma.j.issn.1673-4114.2011.01.013

点击查看大图

计量

文章访问数: 1454
HTML全文浏览量: 114
PDF下载量: 4

放射性碘间接标记抗体方法的研究进展

李楠
李培勇

200025 上海, 上海交通大学瑞金医院核医学科

收稿日期: 2008-06-08

关键词:

摘要: 放射性碘标记单克隆抗体已广泛应用于临床疾病的诊治。内化型抗体的应用越来越受到重视,常规运用的碘直接标记法包括Iodogen标记法、氯胺-T标记法等,制备的碘标记单克隆抗体在体内容易脱碘和损伤抗体免疫活性的特性而阻碍了其在体内应用。如何对抗体进行有效的碘标记来减少体内脱碘和抗体免疫活性损伤,对运用碘标记抗体进行肿瘤治疗是十分重要的,研究表明,间接标记法是一种较为恰当的方案。